Literature DB >> 24743066

Changes in low-density lipoprotein cholesterol levels after discharge for acute myocardial infarction in a real-world patient population.

Suzanne V Arnold, Mikhail Kosiborod, Fengming Tang, Zhenxiang Zhao, Patrick L McCollam, Julie Birt, John A Spertus.   

Abstract

Aggressively managing low-density lipoprotein cholesterol (LDL-C) after myocardial infarction (MI) is a cornerstone of secondary prevention. The changes in LDL-C after MI and the factors associated with LDL-C levels are unknown. Therefore, we directly measured fasting LDL-C levels in 797 MI patients from 24 US hospitals from 2005 to 2008. Mean LDL-C levels at discharge, 1 month, and 6 months were 95.1, 81.9, and 87.1 mg/dL, respectively. In a hierarchical, multivariable, repeated measures model, older age, male sex, and hypertension were associated with lower LDL-C levels, whereas self-reported avoidance of health care because of cost was associated with higher LDL-C. Both the presence and intensity of statin therapy at discharge were strongly associated with LDL-C levels, with adjusted mean 6-month changes of -3.4 mg/dL (95% confidence interval (CI): -12.1, 5.3) for no statins; 1.7 mg/dL (95% CI: -4.7, 8.1) for low statins; -10.2 mg/dL (95% CI: -14.5, -6.0) for moderate statins; and -13.9 mg/dL (95% CI: -19.7, -8.0) for intensive statins (P < 0.001). In conclusion, we found that greater reductions in LDL-C levels after MI were strongly associated with the presence and intensity of statin therapy, older age, male sex, hypertension, and better socioeconomic status. These findings support the use of intensive statin therapy in post-MI patients and provide estimates of the expected LDL-C changes after MI in a real-world population.
© The Author 2014. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cholesterol; cholesterol-lowering drugs; myocardial infarction; statins

Mesh:

Substances:

Year:  2014        PMID: 24743066      PMCID: PMC4036213          DOI: 10.1093/aje/kwu060

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

Review 1.  Current perspectives on statins.

Authors:  D J Maron; S Fazio; M F Linton
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

Review 2.  Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.

Authors:  Pang H Chong
Journal:  Ann Pharmacother       Date:  2002-12       Impact factor: 3.154

3.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Authors:  Michael H Davidson; Kevin C Maki; Thomas A Pearson; Richard C Pasternak; Prakash C Deedwania; James M McKenney; Gregg C Fonarow; David J Maron; Benjamin J Ansell; Luther T Clark; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2005-08-15       Impact factor: 2.778

4.  Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction.

Authors:  Seth S Martin; Kensey Gosch; Krishnaji R Kulkarni; John A Spertus; Robin Mathews; P Michael Ho; Thomas M Maddox; L Kristin Newby; Karen P Alexander; Tracy Y Wang
Journal:  Am Heart J       Date:  2012-11-17       Impact factor: 4.749

5.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

6.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

7.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

8.  Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).

Authors:  Sabina A Murphy; Christopher P Cannon; Stephen D Wiviott; James A de Lemos; Michael A Blazing; Carolyn H McCabe; Robert M Califf; Eugene Braunwald
Journal:  Am J Cardiol       Date:  2007-07-18       Impact factor: 2.778

9.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.

Authors:  Kim A Eagle; Michael J Lim; Omar H Dabbous; Karen S Pieper; Robert J Goldberg; Frans Van de Werf; Shaun G Goodman; Christopher B Granger; P Gabriel Steg; Joel M Gore; Andrzej Budaj; Alvaro Avezum; Marcus D Flather; Keith A A Fox
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2007-08-14       Impact factor: 24.094

View more
  4 in total

Review 1.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

2.  Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study.

Authors:  Masato Nakamura; Junya Ako; Hidenori Arai; Atsushi Hirayama; Yoshitaka Murakami; Atsushi Nohara; Kiyoko Uno; Asuka Ozaki; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2018-12-04       Impact factor: 4.928

3.  The effect of adherence to statin therapy on cardiovascular mortality: quantification of unmeasured bias using falsification end-points.

Authors:  Maarten J Bijlsma; Stijn Vansteelandt; Fanny Janssen; Eelko Hak
Journal:  BMC Public Health       Date:  2016-04-11       Impact factor: 3.295

4.  Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada.

Authors:  David A Alter; Jack V Tu; Maria Koh; Cynthia A Jackevicius; Peter C Austin; Mohammad R Rezai; R Sacha Bhatia; Sharon Johnston; Jacob A Udell; Dennis T Ko
Journal:  J Am Heart Assoc       Date:  2018-05-12       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.